Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August J. Troendle sold 61,655 shares of the business’s stock in a transaction that occurred on Thursday, September 21st. The shares were sold at an average price of $244.27, for a total value of $15,060,466.85. Following the sale, the chief executive officer now owns 5,914,947 shares in the company, valued at $1,444,844,103.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Medpace Stock Up 0.8 %
Shares of MEDP opened at $242.69 on Friday. Medpace Holdings, Inc. has a 12-month low of $141.30 and a 12-month high of $282.73. The firm has a market capitalization of $7.42 billion, a PE ratio of 29.00 and a beta of 1.37. The stock’s fifty day simple moving average is $260.24 and its 200-day simple moving average is $224.83.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Monday, July 24th. The company reported $1.93 EPS for the quarter, beating analysts’ consensus estimates of $1.90 by $0.03. The business had revenue of $460.90 million during the quarter, compared to the consensus estimate of $433.75 million. Medpace had a return on equity of 72.88% and a net margin of 16.06%. The firm’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.46 earnings per share. Analysts anticipate that Medpace Holdings, Inc. will post 8.39 EPS for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on MEDP
Institutional Investors Weigh In On Medpace
Several large investors have recently modified their holdings of the business. Joseph Group Capital Management increased its holdings in shares of Medpace by 1.4% in the second quarter. Joseph Group Capital Management now owns 3,190 shares of the company’s stock worth $766,000 after acquiring an additional 44 shares in the last quarter. Zions Bancorporation N.A. increased its holdings in shares of Medpace by 0.7% in the second quarter. Zions Bancorporation N.A. now owns 6,213 shares of the company’s stock worth $1,492,000 after acquiring an additional 45 shares in the last quarter. Roberts Glore & Co. Inc. IL increased its holdings in shares of Medpace by 0.8% in the second quarter. Roberts Glore & Co. Inc. IL now owns 5,852 shares of the company’s stock worth $1,405,000 after acquiring an additional 45 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Medpace by 0.6% in the first quarter. Ameritas Investment Partners Inc. now owns 8,495 shares of the company’s stock worth $1,597,000 after acquiring an additional 48 shares in the last quarter. Finally, Financial Gravity Asset Management Inc. boosted its position in shares of Medpace by 27.7% during the second quarter. Financial Gravity Asset Management Inc. now owns 240 shares of the company’s stock worth $1,106,000 after buying an additional 52 shares during the period. 77.98% of the stock is currently owned by institutional investors.
Medpace Company Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Featured Articles
- Five stocks we like better than Medpace
- Best Stocks Under $5.00
- 52-week Low Names To Tip The Upside Scale In Your Favor
- What are stock market earnings reports?
- KB Home Price Weakness is a Signal to Buy this Cash Machine
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Analysts Went All In On These Computer Stocks, Save Your Spot
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
